| Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment L Tonneijck, MHA Muskiet, MM Smits, EJ Van Bommel, HJL Heerspink, ... Journal of the American Society of Nephrology 28 (4), 1023-1039, 2017 | 838 | 2017 |
| GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes MHA Muskiet, L Tonneijck, MM Smits, MJ Van Baar, MHH Kramer, ... Nature Reviews Nephrology 13 (10), 605-628, 2017 | 367 | 2017 |
| The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated … EJM van Bommel, MHA Muskiet, MJB van Baar, L Tonneijck, MM Smits, ... Kidney international 97 (1), 202-212, 2020 | 326 | 2020 |
| SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome EJM van Bommel, MHA Muskiet, L Tonneijck, MHH Kramer, M Nieuwdorp, ... Clinical Journal of the American Society of Nephrology 12 (4), 700-710, 2017 | 268 | 2017 |
| Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial MHA Muskiet, L Tonneijck, Y Huang, M Liu, A Saremi, HJL Heerspink, ... The lancet Diabetes & endocrinology 6 (11), 859-869, 2018 | 263 | 2018 |
| Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism NJ van der Zijl, GH Goossens, CCM Moors, DH van Raalte, MHA Muskiet, ... The Journal of Clinical Endocrinology & Metabolism 96 (2), 459-467, 2011 | 253 | 2011 |
| The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? MHA Muskiet, MM Smits, LM Morsink, M Diamant Nature Reviews Nephrology 10 (2), 88-103, 2014 | 242 | 2014 |
| SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management MJB Van Baar, CC Van Ruiten, MHA Muskiet, L Van Bloemendaal, ... Diabetes care 41 (8), 1543-1556, 2018 | 197 | 2018 |
| Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial MM Smits, L Tonneijck, MHA Muskiet, MHH Kramer, PJW Pouwels, ... Diabetologia 59, 2588-2593, 2016 | 146 | 2016 |
| Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial DH Van Raalte, M Brands, NJ Van Der Zijl, MH Muskiet, PJW Pouwels, ... Diabetologia 54, 2103-2112, 2011 | 144 | 2011 |
| Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial L Tonneijck, MM Smits, MHA Muskiet, T Hoekstra, MHH Kramer, ... Diabetologia 59, 1412-1421, 2016 | 133 | 2016 |
| saturated fat, carbohydrates and cardiovascular RS Kuipers, DJ De Graaf, MF Luxwolda, MHA Muskiet, ... Complex Acute Medicine 353, 372, 2011 | 117 | 2011 |
| Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the … RA Scholtes, MHA Muskiet, MJB van Baar, AC Hesp, PJ Greasley, ... Diabetes Care 44 (2), 440-447, 2021 | 116 | 2021 |
| Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo … L Tonneijck, MM Smits, MHA Muskiet, T Hoekstra, MHH Kramer, ... Diabetes care 39 (11), 2042-2050, 2016 | 112 | 2016 |
| Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men MHA Muskiet, L Tonneijck, MM Smits, MHH Kramer, M Diamant, JA Joles, ... Diabetes, Obesity and Metabolism 18 (2), 178-185, 2016 | 106 | 2016 |
| New pharmacological strategies for protecting kidney function in type 2 diabetes MHA Muskiet, DC Wheeler, HJL Heerspink The Lancet Diabetes & Endocrinology 7 (5), 397-412, 2019 | 96 | 2019 |
| Understanding Empa-Reg outcome MHA Muskiet, DH van Raalte, EJM van Bommel, MM Smits, L Tonneijck The lancet Diabetes & endocrinology 3 (12), 928-929, 2015 | 92 | 2015 |
| Pleiotropic effects of type 2 diabetes management strategies on renal risk factors MHA Muskiet, L Tonneijck, MM Smits, MHH Kramer, HJL Heerspink, ... The Lancet Diabetes & Endocrinology 3 (5), 367-381, 2015 | 88 | 2015 |
| Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas MM Smits, L Tonneijck, MHA Muskiet, MHH Kramer, DL Cahen, ... Diabetes, Obesity and Metabolism 18 (3), 224-235, 2016 | 76 | 2016 |
| Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: an 8‐week, randomised, open‐label trial L Tonneijck, MHA Muskiet, MM Smits, T Hoekstra, MHH Kramer, ... Diabetes, Obesity and Metabolism 19 (12), 1669-1680, 2017 | 67 | 2017 |
Mark M. SmitsClinical Research Physician, Internal Medicine / Diabetes Center, VU University Medical CenterVerifisert e-postadresse på vumc.nl